Chiome Bioscience Inc. announced that entrustment agreement has been concluded with Rohto Pharmaceutical Co. Ltd. Under this agreement, therapeutic antibody will be prepared with ADLib- system, Chiome's antibody generation technology. The duration of this agreement is for 1 year.

Under this agreement, Chiome Bioscience will be getting paid by running the ADLib -system to generate antibody against therapeutic target and the affinity maturation. The target of interest is provided by Rohto Pharmaceutical. In case if the candidate antibody proceeds to the commercialize and developmental stages, Rhoto Pharmaceutical may exercise the option agreement by signing a lisence agreement.

The duration of option agreement is for 5 years, starting from the completion of tasks under this agreement. The company will announce the exercise of option agreement in a timely manner.